Orthofix International NV  

(Public, NASDAQ:OFIX)   Watch this stock  
Find more results for Luke T. Faulstick
+4.58 (14.63%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.99 - 36.50
52 week 26.96 - 36.90
Open 31.12
Vol / Avg. 411,752.00/95,313.00
Mkt cap 577.25M
P/E     -
Div/yield     -
EPS -1.27
Shares 18.44M
Beta 0.69
Inst. own 96%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -0.22% -3.72%
Operating margin 2.43% -1.27%
EBITD margin - 9.18%
Return on average assets -0.21% -3.33%
Return on average equity -0.28% -4.40%
Employees 889 -
CDP Score - -


7 Abraham de Veerstraat
+599-9-4658525 (Phone)
+599-9-4616978 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Orthofix International N.V. (Orthofix) is a diversified medical device company focused on developing and delivering repair and regenerative solutions to the spine and orthopedic markets. The Company manages its business by four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation and Spine Fixation. The BioStim SBU offers a portfolio of devices for enhancing bone fusion that utilizes Orthofix�s pulsed electromagnetic technology. The Biologics SBU provides a portfolio of regenerative products that allow physicians to treat a variety of spinal and orthopedic conditions. The Extremity Fixation SBU offers products that allow physicians to treat a variety of orthopedic conditions unrelated to the spine. The Spine Fixation SBU specializes in the design, development and marketing of a portfolio of implant products used in surgical procedures of the spine.

Officers and directors

Ronald A. Matricaria Independent Chairman of the Board
Bio & Compensation  - Reuters
Bradley R. Mason President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Davide Bianchi President - Global Extremity Fixation
Age: 49
Bio & Compensation  - Reuters
Doug Rice Interim Chief Financial Officer, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey M. Schumm Senior Vice President, General Counsel, Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Michael M. Finegan Chief Strategy Officer
Age: 50
Bio & Compensation  - Reuters
Luke T. Faulstick Director
Age: 49
Bio & Compensation  - Reuters
James F. Hinrichs Independent Director
Age: 47
Bio & Compensation  - Reuters
Guy J. Jordan Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Anthony F. Martin Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters